Literature DB >> 11403096

Inverse correlation between the changes of lumbar bone mineral density and serum undercarboxylated osteocalcin after vitamin K2 (menatetrenone) treatment in children treated with glucocorticoid and alfacalcidol.

T Inoue1, T Sugiyama, T Matsubara, S Kawai, S Furukawa.   

Abstract

We have reported that alfacalcidol plus menatetrenone, a vitamin K2 with four isoprene units (menaquinone-4), treatment is useful for improving bone problems in children with skeletal unloading. The aim of this study was to evaluate the effect of menatetrenone on bone metabolism in long-term glucocorticoid-treated children with alfacalcidol treatment. Twenty children who had been treated with fixed dosages of prednisolone and alfacalcidol (0.03 microg/kg/day) for 24 weeks were enrolled in a prospective pilot study, and assigned to receive alfacalcidol (0.03 microg/kg/day) or alfacalcidol (0.03 microg/kg/day) plus menatetrenone (approximately 2 mg/kg/day). Bone biochemical markers and bone mineral density (BMD) were measured at baseline and after the 12-week treatment. In the group receiving alfacalcidol plus menatetrenone, serum carboxylated osteocalcin (OC) (p =0.0022) and lumbar BMD (p=0.0029) increased and serum undercarboxylated OC (p=0.0004) decreased significantly in comparison to the group receiving alfacalcidol; further, the change of lumbar BMD showed an inverse correlation to the change of serum undercarboxylated OC (r=-0.744, p=0.0134) and positive correlations to the baseline values of bone turnover markers such as serum levels of intact OC, bone-specific alkaline phosphatase and type I procollagen carboxyl extension peptide and urinary levels of deoxypyridinoline and N-telopeptide of type I collagen. No adverse effect was observed. This is a small short-term study, but its results suggest that menatetrenone effectively and safely increases lumbar BMD probably through carboxylation of OC in long-term prednisolone-treated children with alfacalcidol treatment who have a high bone turnover. Randomized double-blind controlled trials are needed to confirm our findings.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403096     DOI: 10.1507/endocrj.48.11

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  8 in total

Review 1.  Management of osteoporosis in adults with cystic fibrosis.

Authors:  Travis M Hecker; Robert M Aris
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Effects of vitamin K2 on the development of osteopenia in rats as the models of osteoporosis.

Authors:  Jun Iwamoto; Tsuyoshi Takeda; Yoshihiro Sato
Journal:  Yonsei Med J       Date:  2006-04-30       Impact factor: 2.759

3.  Vitamin K2 Prevents Glucocorticoid-induced Osteonecrosis of the Femoral Head in Rats.

Authors:  Yue-Lei Zhang; Jun-Hui Yin; Hao Ding; Wei Zhang; Chang-Qing Zhang; You-Shui Gao
Journal:  Int J Biol Sci       Date:  2016-01-28       Impact factor: 6.580

4.  Protective effect of VK2 on glucocorticoid-treated MC3T3-E1 cells.

Authors:  Yue-Lei Zhang; Jun-Hui Yin; Hao Ding; Wei Zhang; Chang-Qing Zhang; You-Shui Gao
Journal:  Int J Mol Med       Date:  2016-12-01       Impact factor: 4.101

Review 5.  Glucocorticoid-Induced Osteoporosis: Why Kids Are Different.

Authors:  Leanne M Ward
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-16       Impact factor: 5.555

6.  Comparison of dried plum supplementation and intermittent PTH in restoring bone in osteopenic orchidectomized rats.

Authors:  S Y Bu; E A Lucas; M Franklin; D Marlow; D J Brackett; E A Boldrin; L Devareddy; B H Arjmandi; B J Smith
Journal:  Osteoporos Int       Date:  2007-02-15       Impact factor: 5.071

7.  Effects of plum extract on skeletal system of fetal and newborn mice.

Authors:  Malihezaman Monsefi; Fatemeh Parvin; Maryam Farzaneh
Journal:  Med Princ Pract       Date:  2013-02-13       Impact factor: 1.927

Review 8.  The Impact of Vitamin K2 (Menaquionones) in Children's Health and Diseases: A Review of the Literature.

Authors:  Agnieszka Kozioł-Kozakowska; Katarzyna Maresz
Journal:  Children (Basel)       Date:  2022-01-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.